Medbank (Medbanks Health Technology)

Company Background

Medbanks was established with the goal of leveraging technology and data to improve outcomes in cancer treatment and the management of serious illnesses. As oncology drug innovation accelerated in China, a corresponding need arose for infrastructure that could support patient access to newly approved therapies, gather clinical and real-world evidence, and connect various stakeholders across the healthcare value chain. Medbanks built its operations around these needs.

Over its history, the company grew from a data-oriented startup into a diversified healthcare services organization spanning three primary business segments. It has attracted significant venture and strategic investment over multiple funding rounds prior to its Hong Kong listing.

Core Business Segments

Medbanks operates its business through three interconnected divisions, each serving a different part of the healthcare and life sciences landscape.

1. Physician Research Solutions (PRS)

This segment provides data and research support services primarily to pharmaceutical companies, biotechnology firms, and contract research organizations. The core offering revolves around the collection, structuring, and analysis of clinical and real-world data.

Key services within this segment include:

• Establishment and operation of specialty disease databases, with a strong concentration in oncology.
• Real-world study (RWS) design and execution, helping drug developers understand how their therapies perform outside of controlled clinical trial settings.
• Clinical trial site management and support, connecting pharmaceutical sponsors with hospitals and physicians.
• Data cleaning, standardization, and analytics services that transform fragmented patient records into research-usable datasets.
• Support for post-marketing surveillance and evidence generation required by regulators and payers.

This division builds a valuable evidence base that supports drug development, regulatory submissions, and commercialization decisions.

2. Specialty Pharmacy Business

The specialty pharmacy segment is one of the company's most significant revenue contributors. It operates a network of specialty pharmacies across multiple cities in China, dispensing high-value, complex medications that are often used in the treatment of cancer and other serious conditions.

Services and offerings include:

• Retail and dispensing of specialty pharmaceuticals, including newly launched oncology drugs and innovative therapies.
• Direct-to-patient (DTP) pharmacy services, ensuring patients can access drugs that may not be readily stocked in traditional hospital pharmacies.
• Patient counseling, medication management, and adherence support to help patients correctly follow complex treatment regimens.
• Cold-chain logistics and supply chain management for temperature-sensitive biologics and specialty products.
• Coordination with prescribing physicians and hospitals to facilitate continuity of care.

By operating specialty pharmacies, Medbanks addresses a critical access problem in China's healthcare system, where innovative drugs may face distribution and reimbursement hurdles within the public hospital channel.

3. Pharmacy Benefit Management (PBM) and Health Insurance Services

The third segment focuses on connecting patients, payers, and pharmaceutical manufacturers through insurance-related and benefit-management services. This division reflects the company's ambition to influence how specialty medications are financed and reimbursed.

Offerings in this area include:

• Design and administration of commercial health insurance products, often in partnership with insurance companies, targeting coverage for serious illnesses and specialty medications.
• Pharmacy benefit management services that help control costs and manage the utilization of high-value drugs.
• Patient assistance and affordability programs developed in collaboration with pharmaceutical manufacturers.
• Support for city-customized commercial medical insurance schemes (sometimes referred to as "Huimin Bao" style programs) that broaden patient access to expensive therapies.

This segment helps bridge the affordability gap for patients requiring costly treatments while providing manufacturers with channels to improve drug uptake.

Integrated Business Model

A defining characteristic of Medbanks is the integration among its three segments. Data gathered through the Physician Research Solutions business informs and supports the specialty pharmacy and insurance operations. The specialty pharmacy network generates real-world patient interaction data, while the insurance and PBM services increase patient access to the drugs dispensed through the pharmacies. This creates a reinforcing ecosystem connecting drug developers, physicians, patients, pharmacies, and payers.

Focus on Oncology

Cancer care sits at the heart of Medbanks' strategy. China faces a large and growing burden of oncology cases, and the pace of new cancer drug approvals has increased substantially. Medbanks has concentrated its data assets, pharmacy operations, and patient services on this therapeutic area, building domain expertise in oncology treatment pathways, drug utilization, and patient management.

Technology and Data Infrastructure

The company's operations are underpinned by technology platforms designed to capture and manage clinical and patient data at scale. These platforms enable the structuring of medical records, the operation of disease-specific registries, and the delivery of analytics to pharmaceutical clients. The data infrastructure represents a strategic asset that differentiates the company within China's competitive healthcare services market.

Market Position and Significance

As a listed company on the Hong Kong Stock Exchange, Medbanks (through Sipai Health) is subject to public disclosure requirements and operates with visibility into its financial performance. Its combination of specialty pharmacy distribution, real-world data services, and insurance-linked offerings makes it a multi-faceted participant in China's evolving healthcare landscape. The company serves pharmaceutical and biotechnology clients, hospitals and physicians, insurers, and ultimately patients navigating serious illnesses.

Summary

Medbanks is a Chinese healthcare technology and services company that operates across three integrated business lines: physician research and real-world data solutions, specialty pharmacy operations, and pharmacy benefit management with insurance services. With a strong emphasis on oncology and complex chronic diseases, the company aims to improve patient access to innovative therapies, generate valuable clinical evidence for the life sciences industry, and make high-cost treatments more affordable. Its interconnected model positions it as a bridge among the many stakeholders in China's healthcare and biotech ecosystem.